심장 트로포닌 시장 규모, 점유율, 성장, 세계 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of cardiac troponin Market

The global cardiac troponin market was valued at USD 3.50 billion in 2025 and is projected to grow from USD 3.78 billion in 2026 to USD 7.17 billion by 2034, exhibiting a CAGR of 8.30% during the forecast period. North America dominated the global cardiac troponin market with a 41.15% market share in 2025, supported by the widespread adoption of advanced cardiac diagnostics, increasing cardiovascular disease prevalence, and favorable reimbursement policies.

Cardiac troponin is the gold-standard biomarker used to detect cardiac muscle injury, particularly myocardial infarction (heart attack). Troponin I (cTnI) and Troponin T (cTnT) are highly specific proteins released into the bloodstream following damage to heart muscle cells. Rapid and accurate measurement of these biomarkers enables physicians to diagnose acute coronary syndrome (ACS) at an early stage, allowing timely treatment and improving patient outcomes. The growing burden of cardiovascular diseases, increasing geriatric population, technological advancements in high-sensitivity assays, and expanding adoption of point-of-care testing continue to drive market growth worldwide.

Rising Cardiovascular Disease Burden Drives Market Expansion

The increasing incidence of cardiovascular disorders remains the primary growth driver for the cardiac troponin market. Heart attacks, coronary artery disease, congestive heart failure, and acute coronary syndrome continue to increase globally due to aging populations, sedentary lifestyles, obesity, diabetes, and hypertension.

According to public health statistics, heart disease remains one of the leading causes of mortality worldwide, significantly increasing demand for rapid diagnostic biomarkers. High-sensitivity cardiac troponin assays have transformed emergency cardiac diagnosis by enabling clinicians to detect even minor myocardial injury within a few hours of symptom onset.

Additionally, the growing adoption of point-of-care (POC) diagnostic systems in emergency departments allows healthcare professionals to obtain faster results, improving treatment decisions and reducing hospital admission times.

Market Trends

One of the most important trends shaping the market is the increasing adoption of high-sensitivity cardiac troponin (hs-cTn) assays and point-of-care testing. These technologies provide faster, more accurate detection of myocardial injury compared to conventional laboratory assays.

Healthcare providers are increasingly integrating portable diagnostic devices into emergency rooms, ambulances, and remote healthcare facilities. Continuous product innovation, improved analytical sensitivity, AI-assisted interpretation, and automation are further strengthening the role of cardiac troponin testing in cardiovascular disease management.

Market Drivers

The growing prevalence of cardiovascular diseases continues to create strong demand for cardiac biomarker testing. Early diagnosis remains essential for reducing mortality associated with myocardial infarction and acute coronary syndrome.

Another major growth factor is the continuous introduction of technologically advanced diagnostic products by leading manufacturers. Companies are developing high-sensitivity assays capable of detecting extremely low concentrations of troponin with greater precision, enabling earlier intervention and improved patient outcomes.

Furthermore, the expanding elderly population is expected to significantly increase the number of cardiovascular diagnostic procedures over the coming years, creating sustained demand for cardiac troponin testing.

Market Restraints

Despite strong growth prospects, certain limitations continue to affect market expansion. Conventional cardiac troponin assays often lack sufficient sensitivity during the very early hours following myocardial infarction, limiting their diagnostic accuracy.

Although high-sensitivity assays have addressed many of these concerns, the transition from conventional testing systems requires substantial investment in laboratory infrastructure, equipment upgrades, and healthcare professional training, particularly in developing economies.

Market Opportunities

Growing investments in healthcare infrastructure, expanding emergency diagnostic services, and increasing availability of portable point-of-care testing systems present significant opportunities for market players.

Emerging economies across Asia Pacific, Latin America, and the Middle East are witnessing increasing healthcare modernization, providing manufacturers with opportunities to expand their product portfolios and strengthen distribution networks.

Furthermore, continuous research focused on improving biomarker sensitivity and integrating artificial intelligence into diagnostic platforms is expected to unlock new growth opportunities throughout the forecast period.

Segment Analysis

By Type

The Troponin I segment is projected to dominate the global market with a 73.32% market share in 2026. Troponin I remains the preferred biomarker due to its high specificity for myocardial infarction and growing availability of advanced high-sensitivity and point-of-care testing systems.

Meanwhile, the Troponin T segment is expected to witness strong growth, supported by increasing regulatory approvals, broader clinical adoption, and expanding use in early heart failure diagnosis.

By Setting

The laboratory testing segment is expected to account for 73.68% of the global market in 2026 owing to its superior analytical precision and widespread use in hospital laboratories.

The point-of-care testing segment is anticipated to record the fastest growth during the forecast period due to increasing use in emergency departments, ambulances, and resource-limited healthcare settings where rapid diagnosis is essential.

By Indication

The acute coronary syndrome (ACS) segment is expected to dominate the market with a 55.15% share in 2026. Rising cases of ACS worldwide continue to drive demand for rapid troponin testing for emergency diagnosis and patient triage.

Myocardial infarction remains another major application area, supported by the growing elderly population and increasing prevalence of heart attacks globally.

By End User

The hospitals & clinics segment is projected to hold the largest 63.44% market share in 2026. High patient admissions, increasing cardiovascular emergencies, and widespread adoption of advanced diagnostic assays contribute to segment dominance.

Diagnostic laboratories are also expected to witness healthy growth due to increasing outsourcing of cardiac testing services and expanding laboratory infrastructure.

Regional Analysis

North America dominated the global market with a value of USD 1.44 billion in 2025 and is projected to reach USD 1.56 billion in 2026. Strong healthcare infrastructure, rising cardiovascular disease prevalence, favorable reimbursement systems, and rapid adoption of high-sensitivity assays continue to drive regional growth. The U.S. market is projected to reach USD 1.40 billion in 2026.

Europe accounted for USD 0.92 billion in 2025 and is expected to reach USD 0.99 billion in 2026. Broad adoption of CE-marked diagnostic products, presence of major manufacturers, and increasing use of high-sensitivity assays support regional expansion.

Asia Pacific generated USD 0.74 billion in 2025 and is projected to grow to USD 0.80 billion in 2026, making it the fastest-growing regional market. Increasing cardiovascular disease burden, expanding healthcare infrastructure, growing awareness, and new product launches continue to fuel market growth across China, Japan, and India.

Latin America and the Middle East & Africa are also experiencing steady growth due to improving healthcare facilities, expanding diagnostic capabilities, and increasing government investments in cardiovascular disease management.

Competitive Landscape

The global cardiac troponin market remains moderately competitive, with several multinational diagnostic companies investing heavily in product innovation, regulatory approvals, and strategic collaborations.

Leading market participants include F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthineers AG, bioMerieux SA, Beckman Coulter, QuidelOrtho, Eurolyser Diagnostica GmbH, PerkinElmer Inc., RESPONSE BIOMEDICAL, and LifeSign LLC.

Recent industry developments include new high-sensitivity assays, quality control solutions, innovative antibodies for immunoassays, and expanded regulatory approvals designed to improve diagnostic performance and strengthen competitive positioning.

Conclusion

The global cardiac troponin market is expected to experience robust growth through 2034, driven by the rising prevalence of cardiovascular diseases, increasing adoption of high-sensitivity diagnostic assays, and expanding use of point-of-care testing in emergency medicine. Technological advancements, continuous product innovation, and growing healthcare investments are improving diagnostic accuracy and patient outcomes worldwide. Although conventional assay limitations and infrastructure costs remain challenges, increasing awareness of early cardiac diagnosis, expanding healthcare access, and ongoing innovations in biomarker technology are expected to sustain long-term market growth.

Segmentation

By Type

• Troponin T
• Troponin I

By Setting

• Laboratory Testing
• Point-of-Care (POC) Testing

By Indication

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Others

By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Homecare Settings & Others

By Region

• North America ( By Type, By Setting, By Indication, By End User, By Country)
  • U.S.
  • Canada
• Europe ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
  • GCC
  • South Africa
• Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Cardiovascular Diseases, By Key Countries/Regions, 2024/2025
• 4.2. Technological Advancements in Cardiac Troponin Testing
• 4.3. New Product Launches. By Key Players
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships etc.)
• 4.5. Impact of COVID-19 on the Market

5. Global Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Troponin T
  • 5.1.2. Troponin I
• 5.2. Market Analysis, Insights and Forecast - By Setting
  • 5.2.1. Laboratory Testing
  • 5.2.2. Point-of-Care (POC) Testing
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Myocardial Infarction
  • 5.3.2. Congestive Heart Failure
  • 5.3.3. Acute Coronary Syndrome
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By End-User
  • 5.4.1. Hospitals & Clinics
  • 5.4.2. Diagnostic Laboratories
  • 5.4.3. Homecare Settings & Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Troponin T
  • 6.1.2. Troponin I
• 6.2. Market Analysis, Insights and Forecast - By Setting
  • 6.2.1. Laboratory Testing
  • 6.2.2. Point-of-Care (POC) Testing
• 6.3. Market Analysis, Insights and Forecast - By Indication
  • 6.3.1. Myocardial Infarction
  • 6.3.2. Congestive Heart Failure
  • 6.3.3. Acute Coronary Syndrome
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By End-User
  • 6.4.1. Hospitals & Clinics
  • 6.4.2. Diagnostic Laboratories
  • 6.4.3. Homecare Settings & Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Troponin T
  • 7.1.2. Troponin I
• 7.2. Market Analysis, Insights and Forecast - By Setting
  • 7.2.1. Laboratory Testing
  • 7.2.2. Point-of-Care (POC) Testing
• 7.3. Market Analysis, Insights and Forecast - By Indication
  • 7.3.1. Myocardial Infarction
  • 7.3.2. Congestive Heart Failure
  • 7.3.3. Acute Coronary Syndrome
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By End-User
  • 7.4.1. Hospitals & Clinics
  • 7.4.2. Diagnostic Laboratories
  • 7.4.3. Homecare Settings & Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Rest of Europe

8. Asia Pacific Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Troponin T
  • 8.1.2. Troponin I
• 8.2. Market Analysis, Insights and Forecast - By Setting
  • 8.2.1. Laboratory Testing
  • 8.2.2. Point-of-Care (POC) Testing
• 8.3. Market Analysis, Insights and Forecast - By Indication
  • 8.3.1. Myocardial Infarction
  • 8.3.2. Congestive Heart Failure
  • 8.3.3. Acute Coronary Syndrome
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By End-User
  • 8.4.1. Hospitals & Clinics
  • 8.4.2. Diagnostic Laboratories
  • 8.4.3. Homecare Settings & Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.5.1. China
  • 8.5.2. India
  • 8.5.3. Japan
  • 8.5.4. Australia
  • 8.5.5. Rest of Asia Pacific

9. Latin America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Troponin T
  • 9.1.2. Troponin I
• 9.2. Market Analysis, Insights and Forecast - By Setting
  • 9.2.1. Laboratory Testing
  • 9.2.2. Point-of-Care (POC) Testing
• 9.3. Market Analysis, Insights and Forecast - By Indication
  • 9.3.1. Myocardial Infarction
  • 9.3.2. Congestive Heart Failure
  • 9.3.3. Acute Coronary Syndrome
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By End-User
  • 9.4.1. Hospitals & Clinics
  • 9.4.2. Diagnostic Laboratories
  • 9.4.3. Homecare Settings & Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Troponin T
  • 10.1.2. Troponin I
• 10.2. Market Analysis, Insights and Forecast - By Setting
  • 10.2.1. Laboratory Testing
  • 10.2.2. Point-of-Care (POC) Testing
• 10.3. Market Analysis, Insights and Forecast - By Indication
  • 10.3.1. Myocardial Infarction
  • 10.3.2. Congestive Heart Failure
  • 10.3.3. Acute Coronary Syndrome
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By End-User
  • 10.4.1. Hospitals & Clinics
  • 10.4.2. Diagnostic Laboratories
  • 10.4.3. Homecare Settings & Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. F. Hoffmann-La Roche Ltd.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. bioMerieux SA
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Abbott
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. Siemens Healthineers AG
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Eurolyser Diagnostica GmbH
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. QuidelOrtho (Quidel Corporation)
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. PerkinElmer Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Beckman Coulter, Inc. (Danaher)
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. RESPONSE BIOMEDICAL
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. financials (Based on Availability)
  • 11.2.10. LifeSign LLC.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. financials (Based on Availability)